Results 171 to 180 of about 3,695,210 (335)

Listening to Luddites: Innovation Antibodies and Corporate Success [PDF]

Protracted innovation is an essential activity of every organization in the modern global marketplace and is fueled by a continuous stream of fresh ideas.
Gary OSTER
core  

Clinical Features of Autoimmune Nodopathy With Anti-Neurofascin-155 Antibodies in South Koreans [PDF]

Hyun Ji Lyou, Yeon Hak Chung, Min Ju Kim, Mingi Kim, Mi Young Jeon, Seung Woo Kim, Ha Young Shin, Byoung Joon Kim   +7 more
openalex   +1 more source

Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants [PDF]

, 2017
Carly M. Bliss, Abdoulie Drammeh, Georgina Bowyer, Guillaume Sanou, Ya Jankey Jagne, Oumarou Ouédraogo, Nick J. Edwards, Casimir Tarama, Nicolas Ouédraogo, Mireille Ouédraogo, Jainaba Njie-Jobe, Amidou Diarra, Muhammed O. Afolabi, Alfred B. Tiono, Jean Baptiste Yaro, Uche J. Adetifa, Susanne H. Hodgson, Nicholas Anagnostou, Rachel Roberts, C.J. Duncan, Riccardo Cortese, Nicola K. Viebig, Odile Leroy, Alison M. Lawrie, Katie L. Flanagan, Beate Kampmann, Egeruan B. Imoukhuede, Sodiomon B. Sirima, Kalifa Bojang, Adrian V. S. Hill, Issa Nébié, Katie Ewer   +31 more
openalex   +1 more source

A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy

Molecular Oncology, EarlyView.
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti, Giovanni Germano, Pietro Paolo Vitiello, Alberto Bardelli   +3 more
wiley   +1 more source

Routine repeated echocardiographic monitoring of fetuses exposed to maternal anti-SSA antibodies: time to question the dogma [PDF]

, 2019
N. Costedoat‐Chalumeau, Nathalie Morel, Rebecca Fischer‐Betz, K. Lévesque, Alice Maltret, Munther A. Khamashta, Antonio Brucato   +6 more
openalex   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

Antitumor effects of a monoclonal antibody to human CCR9 in leukemia cell xenografts [PDF]

, 2014
Sonia Chamorro, María Vela, Ana Franco‐Villanueva, Laura Carramolino, Julio Gutiérrez, Lucio Gómez, María D. Lozano, Beatriz Salvador, Mónica García‐Gallo, Carlos Martı́nez-A, Leonor Kremer   +10 more
openalex   +1 more source

A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection

, 2022
Juan Shi, Jian Zheng, Wanbo Tai, Abhishek Kumar Verma, Xiujuan Zhang, Qibin Geng, Gang Wang, Xiao‐Qing Guan, Moffat M. Malisheni, Abby Odle, Wei Zhang, Fang Li, Stanley Perlman, Lanying Du   +13 more
openalex   +2 more sources

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source

Advances in Therapeutic Antibody Discovery and Development Targeting G Protein-Coupled Receptors. [PDF]

Pharmacol Res Perspect
Hutchings CJ, Ünsal S, Rappas M, Barnes M, Waldhoer M, Holland B, Culka M.   +6 more
europepmc   +1 more source